NICE has rejected Amgen’s Kyprolis in second line multiple myeloma treatment in first draft guidance, citing uncertainties over long-term survival benefits. The cost-effectiveness body is ...
Combined with Revlimid and dexamethasone, Kyprolis extended progression-free survival (PFS) by 8.7 months (from 17.6 months to 26.3 months), compared to Revlimid and dexamethasone alone.